GLP-1RAs normalize insulin resistance, and can also modulate dopaminergic signaling and reduce anhedonia, and their effects on glycemic variability and food cravings suggest potential use in addictive disorders
The difference is small and may not be clinically meaningful for many individuals
Initial results are promising
For patients researching GLP-1 weight loss, medical weight loss, semaglutide, or tirzepatide, the goal should be medically supervised metabolic improvement, not simply faster weight loss
These detrimental effects are linked to suppression of the Nrf2 antioxidant pathway
With the prevalence of diabetes and mental health disorders on the rise globally, patients and healthcare providers are increasingly likely to encounter these medications